Vor Biopharma (VOR) Competitors

Vor Biopharma (NASDAQ:VOR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Does the media refer more to VOR or NTLA?

In the previous week, Intellia Therapeutics had 8 more articles in the media than Vor Biopharma. MarketBeat recorded 11 mentions for Intellia Therapeutics and 3 mentions for Vor Biopharma. Intellia Therapeutics' average media sentiment score of 1.48 beat Vor Biopharma's score of 0.90 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, VOR or NTLA?

Vor Biopharma has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Which has stronger valuation & earnings, VOR or NTLA?

Vor Biopharma has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$13.66	-0.14
Intellia Therapeutics	$57.88M	21.05	-$519.02M	-$4.69	-2.42

Is VOR or NTLA more profitable?

Vor Biopharma has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -908.48%. Vor Biopharma's return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Intellia Therapeutics	-908.48%	-57.48%	-45.04%

Do institutionals and insiders have more ownership in VOR or NTLA?

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate VOR or NTLA?

Intellia Therapeutics has a consensus target price of $29.05, suggesting a potential upside of 155.97%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Intellia Therapeutics	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Intellia Therapeutics beats Vor Biopharma on 9 of the 14 factors compared between the two stocks.